Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

Core Insights - Traws Pharma, Inc. has appointed Dr. John Leaman as an independent director to its board, effective October 1, 2025, and has removed the interim titles of its key executives, indicating strong board support for the leadership team [1][2][6] Company Developments - Dr. Leaman brings over a decade of experience in finance, M&A, and corporate strategy, which is expected to be valuable as the company prepares for Phase 2 studies of its lead product, ratutrelvir, aimed at treating COVID-19 [2][3] - The removal of interim titles for CEO Iain Dukes and CFO Charles Parker signifies the board's confidence in their leadership [1][2] Product Pipeline - Ratutrelvir is an investigational oral small molecule designed to treat SARS-CoV-2/COVID-19 without the need for ritonavir, showing promising preclinical and Phase 1 study results [7] - The pharmacokinetic profile of ratutrelvir indicates maintenance of target blood plasma levels approximately 13 times above the EC50 with a dosing regimen of 600 mg/day for ten days, potentially reducing the risk of Long COVID [7] - Tivoxavir marboxil (TXM) is another investigational product targeting bird flu and seasonal influenza, demonstrating potent in vitro activity against various influenza strains [8][9] Market Opportunity - The COVID treatment market represents a potential multi-billion dollar opportunity, driven by ongoing health challenges and the need for effective antiviral therapies [7] - Seasonal influenza and bird flu treatments also present significant market potential, supported by global health initiatives and government tenders [8][9]